The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

Abstract

Objective: Through comparativing the change of the ER, PR and HER-2 expression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, HER-2 expression for breast cancer. Also, the relationship of ER, PR, HER-2 and chemosensitivity is also discussed. Methods: The expressions of ER, PR and HER2 in paraffin sections of breast cancer tissues from 51 patients before and after NAC were detected by immunohistochemical method. The assessment for the relationships between ER, PR, HER-2 and the efficiently of NAC is done. Results: For the 51 peoples, there is no statistical significance for change of ER, PR and HER-2 expression before and after NAC (P > 0.05). There is statistical significance for the differences of chemotherapeutic effectiverate between ER negative and ER positive, PR negative and PR positive, HER2 over-expressed group and HER2 non over-expressed group (P < 0.05). Pathological complete response (pCR) was related to molecular classification and the number of chemotherapy cycles. There is statistically significant or prognisis difference about hormone receptor, HER2 over-expressed and three-negative breast cancer (P < 0.05). Conclusion: NAC maybe could not change the expression of ER and PR, and HER2 for breast cancer patients. The patients with HER-2 over-expressed are not sensitive to chemotherapy, and the patients with ER or PR negative get more benefits from chemotherapy. The breast cancer patients who could obtain pCR could get better prognosis after NAC.

Investigation of efficacy of two different chemotherapy protocols used in neoadjuvant chemotherapy in clinical stages II–IV canine malignant mammary tumours

“…HER2 positivity may be lost by NAC in HER2‐positive BC 40 or the expression of the HER2 receptor may show a decrease 41 after NAC. Moreover, no significant change in ER, PgR or HER2 status may also occur 42 . it is recommended to re‐examine the status of the biomarkers to make targeted adjuvant therapies and better prognosis assessment in HBC 38,40,41 .…”

“…Moreover, no significant change in ER, PgR or HER2 status may also occur. 42 it is recommended to reexamine the status of the biomarkers to make targeted adjuvant therapies and better prognosis assessment in HBC. 38,40,41 In this study, although a decrease in Ki-67 and HER2 expression and an increase in ER expression were observed after NAC in both treatment groups, these changes were not statistically significant (Figure 3).…”